Skip to main content

Advertisement

Table 1 Molecular, functional characteristics and source of origin of the indicated cell lines

From: Evolving neoantigen profiles in colorectal cancers with DNA repair defects

Sample Microsatellite status Altered MSI markers Genome evolvability Split ratio In vitro doubling time Growth rate Source
C10 Stable Stable 0.34 2.33 0.30 ECACC
C106 Stable Stable 0.35 2.50 0.28 ECACC
C125PM Stable Stable 0.34 2.37 0.29 ECACC
C32 Stable Stable 0.18 1.54 0.45 ECACC
C70 Stable Stable 0.4 2.76 0.25 ECACC
C75 Stable Stable 0.36 2.46 0.28 ECACC
C99 Stable NA NA NA NA ECACC
CACO2 Stable Stable 0.26 1.83 0.38 ATCC
CAR1 Stable Stable 0.36 2.47 0.28 JCRB
CCK81 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.34 2.53 0.27 RIKEN
CL14 Stable NA NA NA NA DSMZ
COCM1 Stable Evolving 0.3 2.34 0.30 JCRB
COGA1 Unstable bat26-mono27-nr24 NA NA NA NA Dr. Hubera
COGA2 Stable Stable 0.32 2.22 0.31 Dr. Hubera
COGA5 Stable Stable 0.20 1.69 0.41 Dr. Hubera
COGA8 Stable Stable 0.22 1.67 0.41 Dr. Hubera
COLO201 Stable NA NA NA NA ATCC
COLO94H Stable Stable 0.45 2.81 0.25 CLS
DIFI Stable NA NA NA NA Dr. Baselgab
DLD1 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.07 0.98 0.71 NCI60
HCA24 Stable Evolving 0.33 2.22 0.31 ECACC
HCA46 Stable Stable 0.4 2.41 0.29 ECACC
HCC2998 Stable Stable 0.34 2.33 0.30 NCI60
HDC114 Stable Evolving 0.23 1.69 0.41 DKFZc
HDC142 Stable Evolving 0.35 2.42 0.29 DKFZc
HDC82 Stable NA NA NA NA DKFZc
HRA16 Stable NA NA NA NA ECACC
HROC24 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.16 1.23 0.56 Dr. Linnebacherd
HROC32 Stable Stable 0.62 6.07 0.11 Dr. Linnebacherd
HROC334 Stable Stable 0.45 2.83 0.24 Dr. Linnebacherd
HROC39 Stable Stable 0.5 3.92 0.18 Dr. Linnebacherd
HROC69 Stable Stable 0.33 2.26 0.31 Dr. Linnebacherd
HT115 Stable Evolving 0.24 1.78 0.39 ECACC
HT29 Stable Stable 0.16 1.38 0.50 NCI60
HT55 Stable Stable 0.33 2.21 0.31 ECACC
LIM1215 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.15 1.24 0.56 Dr. Whiteheade
LIM2099 Stable Stable 0.33 2.26 0.31 Dr. Whiteheade
LOVO Unstable nr21-bat25-mono27-nr24 NA NA NA NA ATCC
LS180 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.25 1.90 0.37 ATCC
LS411N Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.32 2.29 0.30 ATCC
MDST8 Stable Stable 0.15 1.31 0.53 ECACC
NCIH716 Stable NA NA NA NA ATCC
OUMS23 Stable Stable 0.26 1.70 0.41 JCRB
OXCO3 Stable Stable 0.23 1.76 0.39 Dr. Cerundolof
RW7213 Stable Stable 0.4 2.60 0.27 Dr. Arangog
SNU1040 Unstable bat26-nr21-bat25-mono27-nr24 Evolving 0.54 4.14 0.17 KCLB
SNU1181 Stable Stable 0.62 4.65 0.15 KCLB
SNU1235 Stable Evolving 0.35 2.33 0.30 KCLB
SNU1411 Stable Evolving 0.44 2.76 0.25 KCLB
SNU1460 Stable NA NA NA NA KCLB
SNU1684 Unstable bat26-nr21-bat25-mono27-nr24 NA NA NA NA KCLB
SNU175 Unstable bat26-nr21-bat25-mono27 NA NA NA NA KCLB
SNU283 Stable NA NA NA NA KCLB
SNU479 Stable NA NA NA NA KCLB
SNU81 Stable Evolving 0.42 2.33 0.30 KCLB
SNU977 Stable Stable 0.42 2.71 0.26 KCLB
SNUC1 Stable NA NA NA NA KCLB
SW1417 Stable NA NA NA NA ATCC
SW1463 Stable NA NA NA NA ATCC
SW480 Stable Stable 0.18 1.64 0.42 ATCC
SW837 Stable Stable 0.27 2.07 0.34 ATCC
V411 Stable Stable 0.22 1.91 0.36 Dr. Markovitzh
V481 Unstable bat26-nr21-bat25-mono27-nr24 NA NA NA NA Dr. Markovitzh
WIDR Stable NA NA NA NA Dr. Bernardsi
  1. Non-commercial cell lines were provided by (a) Dr. L. A. Huber, Cell Biology/Biocenter, Medical University of Innsbruck, Innsbruck, Austria; (b) Dr. Baselga, Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’ Hebron University Hospital, Barcelona, Spain; (c) Dr. M. Schawb, Division of Tumour Genetics - B030 German Cancer Research Center (DKFZ), Heidelberg, Germany; (d) Dr. M. Linnebacher, Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany; (e) Dr. R.H. Whitehead, Depts of Medicine, Cell and Developmental Biology and Cancer Biology, Vanderbilt University, Nashville, USA; (f) Dr. V. Cerundolo, Nuffield Dept of Clinical Medicine, John Radcliffe Hospital, Oxford, UK; (g) Dr. D. Arango, Group of Molecular Oncology, Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d’Hebron, Barcelona, Spain; (h) Dr. S. Markovitz, Case Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Case Western Reserve University, Cleveland, USA; (i) Dr. R. Bernards, Division of Molecular Carcinogenesis B7, Netherlands Cancer Institute, Amsterdam, The Netherlands.